文献速递肝病消化道肿瘤与早癌

肝硬化患者肝癌筛查与癌症相关死亡率降低无关

No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.
PubMed 文献 · Gastroenterology · 2018-07-05

在美国退伍军人健康系统中进行匹配病例对照研究,238例死于肝细胞癌的肝硬化患者与238例对照按诊断年份、种族、年龄、性别、病因、MELD评分和医疗中心匹配。结果显示,筛查超声、筛查甲胎蛋白、任一检测或两者联合的比例在组间均无显著差异,筛查与肝癌相关死亡率降低无关。

要点

  • 病例组与对照组筛查超声比例分别为52.9%与54.2%,无显著差异。
  • 病例组与对照组筛查甲胎蛋白比例分别为74.8%与73.5%,无显著差异。
  • 筛查超声或甲胎蛋白、两者联合的比例在组间均无显著差异。

核心结论

  • 在美国退伍军人健康系统的匹配病例对照研究中,肝硬化患者通过超声、血清甲胎蛋白、任一检测或两者联合筛查肝癌与肝癌相关死亡率降低无关。
  • 作者鼓励在其他医疗系统中开展更多病例对照研究,以评估肝癌筛查的效果。

研究设计与样本

  • 匹配病例对照研究,纳入美国退伍军人事务医疗系统内肝硬化患者。
  • 病例组为2013年1月1日至2015年8月31日死于肝细胞癌的肝硬化患者238例。
  • 对照组为未死于肝细胞癌的肝硬化患者238例,按肝硬化诊断年份、种族和民族、年龄、性别、肝硬化病因、终末期肝病模型评分和退伍军人医疗中心与病例匹配。

主要发现

  • 病例组与对照组在索引日期前4年内接受筛查超声的比例分别为52.9%与54.2%,无显著差异。
  • 病例组与对照组接受筛查血清甲胎蛋白测量的比例分别为74.8%与73.5%,无显著差异。
  • 病例组与对照组接受筛查超声或血清甲胎蛋白测量的比例分别为81.1%与79.4%,无显著差异。
  • 病例组与对照组接受筛查超声和血清甲胎蛋白测量的比例分别为46.6%与48.3%,无显著差异。
  • 在索引日期前1年、2年或3年内接受上述筛查检测的比例在组间也无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者鼓励在其他医疗系统中开展更多病例对照研究,以评估肝癌筛查的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Screening patients with cirrhosis for hepatocellular carcinoma (HCC) has been recommended. We conducted a matched case-control study within the US Veterans Affairs (VA) health care system to determine whether screening by abdominal ultrasonography (USS) and/or by measuring serum level of α-fetoprotein (AFP) was associated with decreased cancer-related mortality in patients with cirrhosis. METHODS: We defined cases (n = 238) as patients with cirrhosis who died of HCC from January 1, 2013 through August 31, 2015 and had been in VA care with a diagnosis of cirrhosis for at least 4 years before the diagnosis of HCC. We matched each case to 1 control (n = 238), defined as a patient with cirrhosis who did not die of HCC and had been in VA care for at least 4 years before the date of the matched case's HCC diagnosis. Controls were matched to cases by year of cirrhosis diagnosis, race and ethnicity, age, sex, etiology of cirrhosis, Model for End-Stage Liver Disease score, and VA medical center. We identified all USS and serum AFP tests performed within 4 years before the date of HCC diagnosis in cases or the equivalent index date in controls and determined by chart extraction (blinded to case or control status) whether these tests were performed for screening. RESULTS: There were no significant differences between cases and controls in the proportions of patients who underwent screening USS (52.9% vs 54.2%), screening measurement of serum AFP (74.8% vs 73.5%), screening USS or measurement of serum AFP (81.1% vs 79.4%), or screening USS and measurement of serum AFP (46.6% vs 48.3%) within 4 years before the index date, with or without adjusting for potential confounders. There also was no difference in receipt of these screening tests within 1, 2, or 3 years before the index date. CONCLUSIONS: In a matched case-control study of the VA health care system, we found that screening patients with cirrhosis for HCC by USS, measurement of serum AFP, either test, or both tests was not associated with decreased HCC-related mortality. We encourage additional case-control studies to evaluate the efficacy of screening for HCC in other health care systems, in which available records are sufficiently detailed to enable identification of the indication for USS and AFP tests.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Moon AM, Weiss NS, Beste LA, et al. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology. 2018. PMID: 29981779. doi:10.1053/j.gastro.2018.06.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。